Home

DEAN J MITCHELL

CIK 1199297 · President and CEO · last filed 2026-06-16

DEAN J MITCHELL is a President and CEO who has filed 111 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for TBPH, was dated Jun 16, 2026. Across all open-market trades the lifetime net is +$591.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $9.9M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$9.93M

Companies

10

Total Filings

111

Lifetime Open-Market Net

$591.5K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TBPH Director 97,213 $16.89 $1.64M $0 12 2026-06-16
PRAX Director 18,622 $295.81 $5.51M $87.0K 9 2026-06-12
PGEN Director 503,183 $5.53 $2.78M $35.2K 13 2024-03-18
ImmunoGen, Inc. (IMGN) Delisted Director 0 $31.23 $0 $125.1K 42 2024-02-12
Kinnate Biopharma Inc. (KNTE) Delisted Director — $2.65 — $0 3 2023-06-13
PRECIGEN, INC. (XON) Delisted Director 49,661 — — $91.6K 12 2019-03-26
ISTA PHARMACEUTICALS INC (ISTA) Delisted Director 4,932 — — $0 5 2011-12-07
Talecris Biotherapeutics Holdings Corp. (TLCR) Delisted Director 3,019 — — $0 2 2010-04-05
ALPHARMA INC (ALO) Delisted President and CEO 80 — — $252.5K 8 2008-12-31
MGI PHARMA INC (MOGN) Delisted Director 3,887 — — $0 1 2007-05-09

Recent Filings

111 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-16 TBPH Grant (A) +6,009 $0 EDGAR
2026-06-12 PRAX Grant (A) +1,371 $0 EDGAR
2025-09-25 PRAX Exer (M) +12,251 $484.0K EDGAR
2025-06-27 PRAX Grant (A) — $0 EDGAR
2025-05-21 TBPH Grant (A) +10,649 $0 EDGAR
2024-06-06 PRAX Grant (A) — $0 EDGAR
2024-05-10 TBPH Grant (A) +10,537 $0 EDGAR
2024-04-05 — Disp (D) — $0
2024-03-18 PGEN Grant (A) +39,510 $56.5K EDGAR
2024-03-12 PGEN Exer (M) +106,837 $0 EDGAR
Showing 1–10 of 111
Page 1 of 12
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.